Gilles Gallant

Company: Mythic Therapeutics

Job title: Chief Development Officer

Seminars:

Panel Discussion: Evaluating the Need for Biomarker & Patient Selection Tools in an Increasingly Busy ADC Field: What are the Predictions for Future ADC Precision Medicine Approaches? 4:30 pm

• What is the current need and appetite for ADC biomarker development and patient selection strategies heading into 2025? • Discussing the different methodologies across machine learning and digital pathology to quantify IHC derived ADC target expression • Addressing the challenges and opportunities of biomarker analysis to select patient populations to benefit from specific ADCs…Read more

day: Conference Day Two pt 2